Does the media refer more to BEAM or PRME?

In the previous week, Beam Therapeutics had 22 more articles in the media than Prime Medicine. MarketBeat recorded 26 mentions for Beam Therapeutics and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.49 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRME or CRSP?

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat CRISPR Therapeutics' score of 0.85 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or PRME?

In the previous week, BioCryst Pharmaceuticals had 14 more articles in the media than Prime Medicine. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 3 Very Positive mention(s) 7 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CDNA or PRME?

CareDx has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CareDx $379.80M 6.85 -$21.35M $2.07 24.28 Prime Medicine $4.07M 139.38 -$201.14M -$1.06 N/A

Is CDNA or PRME more profitable?

CareDx has a net margin of 24.23% compared to Prime Medicine's net margin of -4,613.11%. CareDx's return on equity of 2.87% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets CareDx 24.23% 2.87% 2.17% Prime Medicine -4,613.11% -188.27% -59.11%

Does the media prefer CDNA or PRME?

In the previous week, Prime Medicine had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for Prime Medicine and 3 mentions for CareDx. Prime Medicine's average media sentiment score of 0.94 beat CareDx's score of 0.91 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CareDx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRME or RARE?

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Ultragenyx Pharmaceutical's score of -0.19 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Prime Medicine (PRME) Competitors

$3.13 -0.22 (-6.57%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.18 +0.05 (+1.50%)

As of 09/11/2026 07:58 PM Eastern

Compare

PRME vs. BEAM, CRSP, BCRX, CDNA, and RARE

Should you buy Prime Medicine stock or one of its competitors? Prime Medicine's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), BioCryst Pharmaceuticals (BCRX), CareDx (CDNA), and Ultragenyx Pharmaceutical (RARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prime Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Beam Therapeutics had 22 more articles in the media than Prime Medicine. MarketBeat recorded 26 mentions for Beam Therapeutics and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.49 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$156.04M	15.88	-$79.99M	-$0.86	N/A
Prime Medicine	$4.07M	139.38	-$201.14M	-$1.06	N/A

Beam Therapeutics pays an annual dividend of $0.90 per share and has a dividend yield of 3.8%. Prime Medicine pays an annual dividend of $1.4460 per share and has a dividend yield of 46.2%. Beam Therapeutics pays out -104.7% of its earnings in the form of a dividend. Prime Medicine pays out -136.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Prime Medicine is clearly the better dividend stock, given its higher yield and lower payout ratio.

Beam Therapeutics has a net margin of -54.75% compared to Prime Medicine's net margin of -4,613.11%. Beam Therapeutics' return on equity of -30.71% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Beam Therapeutics presently has a consensus price target of $49.00, suggesting a potential upside of 104.25%. Prime Medicine has a consensus price target of $7.47, suggesting a potential upside of 138.73%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Prime Medicine beats Beam Therapeutics on 10 of the 19 factors compared between the two stocks.

How does Prime Medicine compare to CRISPR Therapeutics?

Prime Medicine (NASDAQ:PRME) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

CRISPR Therapeutics has a net margin of -3,368.72% compared to Prime Medicine's net margin of -4,613.11%. CRISPR Therapeutics' return on equity of -24.39% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Prime Medicine has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Prime Medicine presently has a consensus price target of $7.47, suggesting a potential upside of 138.73%. CRISPR Therapeutics has a consensus price target of $68.06, suggesting a potential upside of 31.58%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts plainly believe Prime Medicine is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

Prime Medicine has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.07M	139.38	-$201.14M	-$1.06	N/A
CRISPR Therapeutics	$3.51M	1,424.73	-$581.60M	-$4.76	N/A

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat CRISPR Therapeutics' score of 0.85 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Prime Medicine beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, BioCryst Pharmaceuticals had 14 more articles in the media than Prime Medicine. MarketBeat recorded 18 mentions for BioCryst Pharmaceuticals and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	3 Very Positive mention(s)	7 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals currently has a consensus price target of $20.40, suggesting a potential upside of 151.23%. Prime Medicine has a consensus price target of $7.47, suggesting a potential upside of 138.73%. Given BioCryst Pharmaceuticals' higher possible upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

BioCryst Pharmaceuticals has higher revenue and earnings than Prime Medicine. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.37	$263.86M	-$1.50	N/A
Prime Medicine	$4.07M	139.38	-$201.14M	-$1.06	N/A

BioCryst Pharmaceuticals has a net margin of -40.90% compared to Prime Medicine's net margin of -4,613.11%. BioCryst Pharmaceuticals' return on equity of -86.89% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

BioCryst Pharmaceuticals and Prime Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to CareDx?

CareDx (NASDAQ:CDNA) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

In the previous week, Prime Medicine had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for Prime Medicine and 3 mentions for CareDx. Prime Medicine's average media sentiment score of 0.94 beat CareDx's score of 0.91 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CareDx	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Prime Medicine shares are owned by institutional investors. 2.4% of CareDx shares are owned by company insiders. Comparatively, 16.0% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CareDx presently has a consensus target price of $51.20, indicating a potential upside of 1.87%. Prime Medicine has a consensus target price of $7.47, indicating a potential upside of 138.73%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

CareDx has a net margin of 24.23% compared to Prime Medicine's net margin of -4,613.11%. CareDx's return on equity of 2.87% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	24.23%	2.87%	2.17%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

CareDx has a beta of 2.43, meaning that its stock price is 143% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market.

CareDx has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	6.85	-$21.35M	$2.07	24.28
Prime Medicine	$4.07M	139.38	-$201.14M	-$1.06	N/A

Summary

CareDx and Prime Medicine tied by winning 8 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Ultragenyx Pharmaceutical?

Prime Medicine (NASDAQ:PRME) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Prime Medicine currently has a consensus target price of $7.47, suggesting a potential upside of 138.73%. Ultragenyx Pharmaceutical has a consensus target price of $36.63, suggesting a potential upside of 156.16%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52

Prime Medicine has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Prime Medicine is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.07M	139.38	-$201.14M	-$1.06	N/A
Ultragenyx Pharmaceutical	$673M	2.09	-$575M	-$5.84	N/A

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to Prime Medicine's net margin of -4,613.11%. Prime Medicine's return on equity of -188.27% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

Prime Medicine has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 4 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.94 beat Ultragenyx Pharmaceutical's score of -0.19 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Prime Medicine and Ultragenyx Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$567.71M	$3.84B	$7.14B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-2.95	14.25	275.24	25.29
Price / Sales	139.38	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	4.67	15.12	10.33	6.20
Net Income	-$201.14M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-15.41%	-4.34%	-3.32%	-2.35%
1 Month Performance	-2.19%	-0.02%	-0.41%	-2.77%
1 Year Performance	-23.10%	40.64%	19.21%	7.63%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	2.8077 of 5 stars	$3.13 -6.6%	$7.47 +138.7%	-23.3%	$567.71M	$4.07M	N/A	N/A	News Coverage Analyst Upgrade
BEAM Beam Therapeutics	2.3429 of 5 stars	$29.59 +2.0%	$49.00 +65.6%	+11.3%	$3.05B	$156.04M	N/A	510	Trending News Analyst Forecast Options Volume
CRSP CRISPR Therapeutics	2.3557 of 5 stars	$57.24 +0.7%	$68.06 +18.9%	-7.5%	$5.52B	$11M	N/A	460
BCRX BioCryst Pharmaceuticals	2.4753 of 5 stars	$9.99 +0.7%	$20.60 +106.2%	+0.6%	$2.56B	$874.84M	N/A	530	News Coverage Analyst Forecast
CDNA CareDx	2.4911 of 5 stars	$49.19 +0.4%	$51.20 +4.1%	+271.5%	$2.55B	$458.09M	23.82	740

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, CRSP, BCRX, CDNA, and RARE

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to CRISPR Therapeutics?

Summary

How does Prime Medicine compare to BioCryst Pharmaceuticals?

Summary

How does Prime Medicine compare to CareDx?

Summary

How does Prime Medicine compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, CRSP, BCRX, CDNA, and RARE

How does Prime Medicine compare to Beam Therapeutics?

Does the media refer more to BEAM or PRME?

Which has more volatility and risk, BEAM or PRME?

Which has stronger earnings and valuation, BEAM or PRME?

Is BEAM or PRME a better dividend stock?

Is BEAM or PRME more profitable?

Do insiders & institutionals believe in BEAM or PRME?

Do analysts recommend BEAM or PRME?

Summary

How does Prime Medicine compare to CRISPR Therapeutics?

Is PRME or CRSP more profitable?

Which has more risk & volatility, PRME or CRSP?

Do analysts recommend PRME or CRSP?

Which has higher valuation & earnings, PRME or CRSP?

Does the media refer more to PRME or CRSP?

Do insiders & institutionals hold more shares of PRME or CRSP?

Summary

How does Prime Medicine compare to BioCryst Pharmaceuticals?

Does the media prefer BCRX or PRME?

Do analysts rate BCRX or PRME?

Which has stronger valuation and earnings, BCRX or PRME?

Is BCRX or PRME more profitable?

Which has more risk & volatility, BCRX or PRME?

Do insiders and institutionals have more ownership in BCRX or PRME?

Summary

How does Prime Medicine compare to CareDx?

Does the media prefer CDNA or PRME?

Do insiders & institutionals hold more shares of CDNA or PRME?

Do analysts rate CDNA or PRME?

Is CDNA or PRME more profitable?

Which has more risk and volatility, CDNA or PRME?

Which has higher valuation and earnings, CDNA or PRME?

Summary

How does Prime Medicine compare to Ultragenyx Pharmaceutical?

Do analysts prefer PRME or RARE?

Which has better valuation & earnings, PRME or RARE?

Is PRME or RARE more profitable?

Which has more risk and volatility, PRME or RARE?

Does the media favor PRME or RARE?

Do insiders and institutionals have more ownership in PRME or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools